The Two Divergent Paths Priced Into Eli Lilly Stock

If you hold shares, you’re already exposed to a potential future where the stock is either far higher or far lower, and the options market is pricing both as real possibilities.

1.1 years from now, the options market sees a future where Eli Lilly (LLY) stock is trading near $1804.04, and another where it’s near $780. For a shareholder with a current price of about $1191.94, this two-sided risk is inherent to their position, whether they use options or not.

This wide range isn’t a forecast, but a price tag on uncertainty. The options chain suggests a 68% probability that LLY will finish the next 1.1 years somewhere inside that band. Reaching the ceiling would mean a gain of about 51%, or $612 per share, while hitting the floor would mean a loss of 35%, or about $412 per share. The sheer size of this potential swing is the story for any current holder.

Why the Market Can’t Decide Between Rocket Fuel and a Reality Check

This uncertainty reflects a high-stakes debate. On one hand, the company’s growth is substantial: management reported revenue grew 48% compared to Q2 of 2025, with its blockbuster incretin drugs Mounjaro and Zepbound combining for $14.8 billion in quarterly revenue alone. The company also raised its full-year revenue guidance to between $85 billion and $87 billion.

But questions are surfacing. Analysts on the same call noted a “somewhat slower than anticipated” U.S. launch for the new oral drug Foundayo. Another pointed out that the updated guidance could imply a revenue deceleration for the back half of the year. This tension between a proven growth engine and legitimate questions about its sustainability creates the wide, two-sided potential.

Is This Level of Priced Risk Normal for Lilly?

The options market provides a measure of this tension. The stock’s implied volatility for the next 1.1 years is 39%, only slightly higher than its realized volatility of 36% over the past year. This suggests the market expects the stock’s already volatile character to continue, rather than pricing in a sudden panic. For a stock that has returned +57% over the trailing twelve months, a high degree of movement is its normal state. Within that wide range, however, traders show a notable lean toward optimism, paying about 1.7 times as much for upside calls as for downside puts.

What a Shareholder Can Actually Do About This Uncertainty

While shareholders cannot control how this uncertainty resolves, they can control their exposure to it. A position with such significant upside and downside potential is a question of sizing: how much of a portfolio is one comfortable seeing swing by 35% or 51%? Answering this honestly is more critical than guessing the stock’s direction. The sensible response for an investor is not to predict, but to prepare, ensuring a single stock’s journey doesn’t derail an entire financial plan through disciplined sizing and diversification.

That raises the obvious question for your own portfolio: are the other stocks you hold carrying this same kind of priced-in risk, or are they calmer than this one? Our Expected Move rankings show the nearly one-year move the options market is pricing into names across the market, so you can see exactly where your own holdings stand. And if it is exposure to healthcare as a whole you want rather than this one name, a healthcare ETF like XLV covers that single sector. Going broader than any one sector, to a quality-first mix across the whole market, is where the portfolio below comes in.

Protect Your Portfolio From Extreme Volatility

Options prices are telling you how hard this stock can move, and the professional response is to check how much of one name you hold before the swings arrive. That check is exactly what the Trefis Wealth team provides, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.